Acute Stroke of Carotid Artery Bifurcation Origin Treated With Use of the Micronet-covered CGuard Stent Under Transient Flow Reversal Linked With Thrombus Retrieval SAFEGUARD-STROKE Study

What this Trial Is About

Researchers are evaluating the use of the Micronet-covered CGuard stent to treat patients with acute stroke caused by blockage at the carotid artery bifurcation. This type of stroke is challenging to treat and often has poor outcomes with standard intravenous clot-busting treatments. The study aims to assess this device in an urgent, real-world setting where current treatment options and timing for intervention are not well established. This is a single-center, open-label registry study including consecutive patients who qualify for endovascular management. The treatment involves placing the Micronet-covered stent to seal the clot-causing lesion while using proximal cerebral protection through transient flow reversal achieved by balloon catheters like MoMa or FlowGate. When needed, clot removal from the arteries supplying the brain is performed using aspiration devices or stentrievers. Patient management, including anesthesia choice and medications, follows established stroke guidelines and routine clinical practice at the study center. Participants will undergo clinical evaluations and brain and blood vessel imaging such as CT or MRI at presentation and during follow-up. The study will track safety and effectiveness outcomes including clinical status at 90 days, procedural success, stroke recurrence, and complications over up to 5 years. Follow-up visits may include imaging and assessments as per routine care. The total participation duration depends on each patients clinical course and follow-up schedule.

Acute Stroke of CArotid Artery Bifurcation Origin Treated With Use oF the MicronEt-covered CGUARD (SAFEGUARD-STROKE)